Security
Sana Biotechnology, Inc. Common Stock · SANA
SANANASDAQCommon stockCurrentCIK 1770121Updated Oct 7, 2026
SANA price & chart
Loading TradingView…
NASDAQ:SANA on TradingView ↗About the company
Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients. We share a vision of repairing and controlling genes, replacing missing or damaged cells, and making our therapies broadly available to patients. We are a passionate group of people working together to create an enduring company that changes how the world treats disease. Sana has operations in Seattle, WA, Cambridge, MA, and South San Francisco, CA.
In the news
Sana Biotechnology to Present at June 2026 Investor Conferences ↗
Levi & Korsinsky Notifies Shareholders of Sana Biotechnology, Inc.(SANA) of a Class Action Lawsuit and an Upcoming Deadline News provided by Levi & Korsinsky, LLP May 20, 2025, 05:45 ET Share this article Share to X Share this article Share to X NEW YORK , May 20, 2025 /PRNewswire/ -- Levi & Korsins ↗
Sana Biotechnology, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before May 20, 2025 to Discuss Your Rights - SANA News provided by The Gross Law Firm May 19, 2025, 13:04 ET Share this article Share to X Share this article Share to X NEW YORK , May 19, 2025 /PRNewswire/ --The ↗
Recent filings
4 filing
Regulation FD Disclosure
Items 7.01, 9.01
4 filing
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 435,432,000Source | 559,392,000Source | 431,522,000Source | 361,645,000Source | 618,667,000Source | 373,593,000Source | 445,470,000Source | 681,377,000Source | 416,890,000Source | 501,020,000Source | 565,299,000Source | 822,720,000Source |
| Property, Plant and Equipment, NetUSD | 29,931,000Source | 82,826,000Source | 25,164,000Source | 33,081,000Source | 85,909,000Source | 25,673,000Source | 73,687,000Source | 81,649,000Source | 26,906,000Source | 77,308,000Source | 70,689,000Source | 66,917,000Source |
| GoodwillUSD | 140,627,000Source | 140,627,000Source | 140,627,000Source | 140,627,000Source | 140,627,000Source | 140,627,000Source | 140,627,000Source | 140,627,000Source | 140,627,000Source | 140,627,000Source | 140,627,000Source | 140,627,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 59,195,000Source | 59,195,000Source | 59,195,000Source | 59,195,000Source | 59,195,000Source | 59,195,000Source | 59,195,000Source | 59,195,000Source | 59,195,000Source | 59,195,000Source | 59,195,000Source | 59,195,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 103,357,000Source | 126,996,000Source | 57,073,000Source | 71,271,000Source | 134,958,000Source | 83,800,000Source | 96,131,000Source | 177,054,000Source | 71,870,000Source | 127,566,000Source | 133,517,000Source | 176,765,000Source |
| Assets, CurrentUSD | 161,759,000Source | 210,149,000Source | 170,629,000Source | 82,502,000Source | 263,453,000Source | 111,690,000Source | 112,731,000Source | 321,263,000Source | 148,676,000Source | 160,808,000Source | 213,515,000Source | 444,437,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 4,510,000Source | 7,310,000Source | 5,944,000Source | 5,633,000Source | 7,978,000Source | 6,359,000Source | 3,835,000Source | 6,349,000Source | 6,099,000Source | 4,479,000Source | 4,488,000Source | 14,374,000Source |
| Operating Lease, Right-of-Use AssetUSD | 40,704,000Source | 61,040,000Source | 35,355,000Source | 43,021,000Source | 63,154,000Source | 35,845,000Source | 54,837,000Source | 71,565,000Source | 38,313,000Source | 57,961,000Source | 74,903,000Source | 92,486,000Source |
| Other Assets, NoncurrentUSD | 3,216,000Source | 5,555,000Source | 552,000Source | 3,219,000Source | 6,329,000Source | 563,000Source | 4,393,000Source | 7,078,000Source | 3,173,000Source | 5,121,000Source | 6,370,000Source | 4,599,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 240,124,000Source | 266,914,000Source | 276,954,000Source | 239,089,000Source | 279,018,000Source | 254,353,000Source | 236,391,000Source | 306,235,000Source | 256,006,000Source | 250,516,000Source | 277,793,000Source | 323,405,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 26,000Source | 22,000Source | 30,000Source | 23,000Source | 22,000Source | 27,000Source | 23,000Source | 22,000Source | 27,000Source | 22,000Source | 20,000Source | 19,000Source |
| Additional Paid in CapitalUSD | 1,985,452,000Source | 1,848,183,000Source | 2,114,465,000Source | 1,870,572,000Source | 1,835,503,000Source | 2,015,441,000Source | 1,863,295,000Source | 1,820,701,000Source | 2,009,845,000Source | 1,855,318,000Source | 1,625,637,000Source | 1,558,459,000Source |
| Retained Earnings (Accumulated Deficit)USD | -1,790,191,000Source | -1,555,781,000Source | -1,959,861,000Source | -1,748,039,000Source | -1,495,857,000Source | -1,896,226,000Source | -1,654,239,000Source | -1,445,566,000Source | -1,849,016,000Source | -1,604,850,000Source | -1,338,091,000Source | -1,054,836,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 21,000Source | 54,000Source | -66,000Source | 0Source | -19,000Source | -2,000Source | 0Source | -15,000Source | 28,000Source | 14,000Source | -60,000Source | -4,327,000Source |
| Stockholders' Equity Attributable to ParentUSD | 195,308,000Source | 292,478,000Source | 154,568,000Source | 122,556,000Source | 339,649,000Source | 119,240,000Source | 209,079,000Source | 375,142,000Source | 160,884,000Source | 250,504,000Source | 287,506,000Source | 499,315,000Source |
| Liabilities and EquityUSD | 435,432,000Source | 559,392,000Source | 431,522,000Source | 361,645,000Source | 618,667,000Source | 373,593,000Source | 445,470,000Source | 681,377,000Source | 416,890,000Source | 501,020,000Source | 565,299,000Source | 822,720,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 35,513,000Source | 47,004,000Source | 123,752,000Source | 33,444,000Source | 50,689,000Source | 86,265,000Source | 33,156,000Source | 52,901,000Source | 78,726,000Source | 45,433,000Source | 64,487,000Source | 111,504,000Source |
| Operating Lease, Liability, CurrentUSD | 14,368,000Source | 10,601,000Source | 14,507,000Source | 13,832,000Source | 9,998,000Source | 14,878,000Source | 13,003,000Source | 13,167,000Source | 14,938,000Source | 12,534,000Source | 13,195,000Source | 12,393,000Source |
| Accounts Payable, CurrentUSD | 1,858,000Source | 2,991,000Source | 1,359,000Source | 2,270,000Source | 3,817,000Source | 2,123,000Source | 989,000Source | 6,095,000Source | 1,669,000Source | 5,210,000Source | 4,108,000Source | 2,857,000Source |
| Operating Lease, Liability, NoncurrentUSD | 67,868,000Source | 85,483,000Source | 59,232,000Source | 71,660,000Source | 88,559,000Source | 60,450,000Source | 78,311,000Source | 92,922,000Source | 63,924,000Source | 81,663,000Source | 90,901,000Source | 95,860,000Source |
| Other Liabilities, NoncurrentUSD | 7,876,000Source | 7,456,000Source | 9,480,000Source | 8,242,000Source | 7,302,000Source | 9,805,000Source | 9,443,000Source | — | 10,600,000Source | 9,896,000Source | — | — |
| Additional Financial Items | ||||||||||||
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | — | — | — | 24,713,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -47,210,000Source | -49,389,000Source | -244,166,000Source | -266,759,000Source | -283,255,000Source | -269,476,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 5,662,000Source | 7,022,000Source | 25,464,000Source | 37,678,000Source | 35,533,000Source | 38,337,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 454,000Source | -4,224,000Source | -3,545,000Source | 1,377,000Source | 1,027,000Source | 1,058,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -37,379,000Source | -48,657,000Source | -143,828,000Source | -223,153,000Source | -253,582,000Source | -290,050,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 49,437,000Source | 16,603,000Source | -40,238,000Source | 17,453,000Source | 172,012,000Source | 210,562,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 288,000Source | 136,000Source | 938,000Source | 33,430,000Source | 20,032,000Source | 20,876,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | -128,000Source | 982,000Source | 128,733,000Source | 199,749,000Source | 31,646,000Source | 4,913,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 11,930,000Source | -31,072,000Source | -55,333,000Source | -5,951,000Source | -49,924,000Source | -74,575,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 107,552,000Source | 130,828,000Source | 61,268,000Source | 75,466,000Source | 87,995,000Source | 100,326,000Source | 76,065,000Source | 131,398,000Source | 137,349,000Source | 187,273,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 5,476,000Source | 10,770,000Source | 5,342,000Source | 6,629,000Source | 5,662,000Source | 7,022,000Source | 25,464,000Source | 37,678,000Source | 35,533,000Source | 38,337,000Source |
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| DepreciationUSD | — | — | 3,200,000Source | 4,100,000Source | 2,200,000Source | 2,900,000Source | 2,391,000Source | 3,649,000Source | 12,800,000Source | 17,400,000Source | 24,600,000Source | 15,625,000Source |
| General and Administrative ExpenseUSD | — | — | 10,285,000Source | 14,052,000Source | 10,778,000Source | 10,341,000Source | 11,462,000Source | 11,484,000Source | 44,296,000Source | 64,040,000Source | 73,299,000Source | 71,561,000Source |
| GoodwillUSD | — | — | 140,627,000Source | 140,627,000Source | 140,627,000Source | 140,627,000Source | 140,627,000Source | 140,627,000Source | 140,627,000Source | 140,627,000Source | 140,627,000Source | 140,627,000Source |
| Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)USD | — | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Marketable Securities, Unrealized Gain (Loss)USD | — | — | — | — | — | — | — | — | — | — | — | -2,961,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -42,152,000Source | -59,924,000Source | -63,635,000Source | -93,800,000Source | -47,210,000Source | -49,389,000Source | -244,166,000Source | -266,759,000Source | -283,255,000Source | -269,476,000Source |
| Operating ExpensesUSD | — | — | 43,515,000Source | 61,761,000Source | 65,420,000Source | 94,975,000Source | 48,614,000Source | 50,630,000Source | 250,319,000Source | 272,723,000Source | 293,141,000Source | 272,564,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 360,000Source | -742,000Source | 656,000Source | 598,000Source | 453,000Source | 249,000Source | 2,305,000Source | -4,507,000Source | -52,000Source | -674,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | 126,404,000Source | — | 4,626,000Source | 601,000Source |
| Net Income (Loss) Available to Common Stockholders, Basic | — | — | — | —Source | — | — | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -43,515,000Source | -61,761,000Source | -65,420,000Source | -94,975,000Source | -48,614,000Source | -50,630,000Source | -250,319,000Source | -272,723,000Source | -293,141,000Source | -272,564,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 360,000Source | -742,000Source | 656,000Source | 598,000Source | 453,000Source | 249,000Source | 2,305,000Source | -4,507,000Source | -52,000Source | -674,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -42,152,000Source | -59,924,000Source | -63,635,000Source | -93,800,000Source | -47,210,000Source | -49,389,000Source | -244,166,000Source | -266,759,000Source | -283,255,000Source | -269,476,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.16Source | -0.25Source | -0.22Source | -0.39Source | -0.17Source | -0.21Source | -0.96Source | -1.16Source | -1.46Source | -1.43Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.16Source | -0.25Source | -0.22Source | -0.39Source | -0.17Source | -0.21Source | -0.96Source | -1.16Source | -1.46Source | -1.43Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 260,494,000Source | 235,412,000Source | 295,667,000Source | 238,409,000Source | 276,856,000Source | 237,578,000Source | 253,234,000Source | 230,891,000Source | 194,541,000Source | 188,344,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 260,494,000Source | 235,412,000Source | 295,667,000Source | 238,409,000Source | 276,856,000Source | 237,578,000Source | 253,234,000Source | 230,891,000Source | 194,541,000Source | 188,344,000Source |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| General and Administrative ExpenseUSD | — | — | 10,285,000Source | 14,052,000Source | 10,778,000Source | 10,341,000Source | 11,462,000Source | 11,484,000Source | 44,296,000Source | 64,040,000Source | 73,299,000Source | 71,561,000Source |
| Interest Income (Expense), Nonoperating, NetUSD | — | — | 1,003,000Source | 2,579,000Source | 1,129,000Source | 577,000Source | 951,000Source | 992,000Source | 3,848,000Source | 10,471,000Source | 9,938,000Source | 3,762,000Source |
| Operating ExpensesUSD | — | — | 43,515,000Source | 61,761,000Source | 65,420,000Source | 94,975,000Source | 48,614,000Source | 50,630,000Source | 250,319,000Source | 272,723,000Source | 293,141,000Source | 272,564,000Source |
| Research and Development ExpenseUSD | — | — | 30,106,000Source | 53,206,000Source | 30,729,000Source | 29,761,000Source | 28,719,000Source | 37,189,000Source | 131,980,000Source | 217,564,000Source | 268,823,000Source | 285,885,000Source |
| Net Income (Loss) Available to Common Stockholders, Basic | — | — | — | —Source | — | — | — | — | — | — | — | — |
Filing attachments
d170343dex991.htm · 8-K · 2026-09-08
EX-99.1 2 d170343dex991.htm EX-99.1 EX-99.1 Corporate Presentation September 2026 Exhibit 99.1 This presentation contains forward-looking statements about Sana Biotechnology, Inc. (the “Company,” “we,” “us,” or “our”) within the meaning of the federal securities laws. All statements other than statements of historical facts contained in this presentation, including, among others, statements regarding the Company’s strategy, expectations, cash runway and future financial condition, future o…
Read attachment ↗sana-ex99_1.htm · 8-K · 2026-08-10
EX-99.1 2 sana-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Sana Biotechnology Reports Second Quarter 2026 Financial Results and Business Updates Continued progress toward starting SC451 Phase 1/2 trial, including GLP toxicology studies, SC451 process transfer to the contract manufacturer, and clinical trial readiness Continued progress toward starting clinical study for SG293 in non-Hodgkin lymphoma and generating initial clinical data, including manufacturing and clinical trial readiness A…
Read attachment ↗sana-ex99_1.htm · 8-K · 2026-05-11
EX-99.1 2 sana-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Sana Biotechnology Reports First Quarter 2026 Financial Results and Business Updates Announced strategic collaboration with Mayo Clinic, focused on improving care in type 1 diabetes and accelerating development of SC451 Continued progress toward starting SC451 Phase 1 trial later this year, including manufacturing readiness, non-clinical testing, and clinical trial preparation Announced positive clinical results at 14 months from on…
Read attachment ↗sana-ex99_1.htm · 8-K · 2026-02-17
Exhibit 99.1 Sana Biotechnology Appoints Brian Piper as Executive Vice President, Chief Financial Officer SEATTLE, February 17, 2026 - Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced the appointment of Brian Piper as Executive Vice President, Chief Financial Officer. Mr. Piper brings to Sana a breadth of biopharmaceutical financial and operational expertise with over 25 years of experience in various pos…
Read attachment ↗sana-ex99_1.htm · 8-K · 2026-01-14
Corporate Presentation January 2026 Exhibit 99.1 This presentation contains forward-looking statements about Sana Biotechnology, Inc. (the “Company,” “we,” “us,” or “our”) within the meaning of the federal securities laws. All statements other than statements of historical facts contained in this presentation, including, among others, statements regarding the Company’s strategy, expectations, cash runway and future financial condition, future operations, and prospects, are forward-looking state…
Read attachment ↗